Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.39 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201064 | 0.86 | PDE4D (0.54) | LMNANR1I2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2202595 | 0.81 | LMNA (0.68) | LMNANR1I2HPGDMEN1KMT2A | |
| SCHEMBL2201663 | 0.78 | TACR1 (0.42) | NR1I2FFAR4ERAP1ERAP2KMT2A | |
| SCHEMBL27993086 | 0.78 | LMNA (0.52) | LMNAHPGDMEN1KMT2AALKBH1 | |
| SCHEMBL2202206 | 0.77 | RAB9A (0.49) | LMNAKMT2AALKBH1 | |
| SCHEMBL2202029 | 0.75 | POLB (0.59) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3277283 | 0.73 | MAPT (0.54) | LMNAHPGDSMN1; SMN2SCN9AMEN1 | |
| SCHEMBL2201389 | 0.70 | LMNA (0.43) | LMNASCN9AMEN1KMT2AALKBH1 | |
| SCHEMBL8385492 | 0.69 | TNKS (0.46) | NR1I2FFAR4 | |
| SCHEMBL5904628 | 0.69 | ATM (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977358-B2 | Pyrazol derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2182953-A2 | NEW PYRAZOL DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20090029963-A1 | PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | US | disclosed |
| WO-2009013211-A2 | NEW PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029963-A1 | PYRAZOL DERIVATIVES | CCR1, CCR3, CCRL2 | LMNA 4701/4885NR1I2 29/4885HPGD 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.